PSMA PET/CT Guided Intensification of Therapy in Patients at Risk of Advanced Prostate Cancer

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

800

Participants

Timeline

Start Date

January 6, 2021

Primary Completion Date

January 31, 2029

Study Completion Date

January 31, 2029

Conditions
Prostate Cancer
Interventions
DIAGNOSTIC_TEST

PSMA PET/CT guided intensification of therapy

PSMA PET/CT prior to treatment.

OTHER

Control Arm

Control - Treatment without PSMA PET/CT

Trial Locations (19)

Unknown

BC Cancer Kelowna, Kelowna

BC Cancer Vancouver, Vancouver

CHU de Québec, Québec

Tom Baker Cancer Center, Calgary

Cross Cancer Institute, Edmonton

CHUM, Montreal

Jewish General Hospital, Montreal

Windsor Regional Cancer Centre, Windsor

Cancer Care Manitoba, Winnipeg

L4M 6M2

Royal Victoria Regional Health Centre, Barrie

L8N 4A6

St-Joseph's Healthcare, Hamilton

L8V 5C2

Juravinski Cancer Centre, Hamilton

N2G 1G3

Grand River Regional Cancer Centre, Kitchener

N6A 5W9

London Health Sciences Centre, London

M5G 1X6

Princess Margaret Cancer Centre, Toronto

H7M 3L9

Hopital de la Cité de la Santé, Laval

H2X 3H7

Charles Lemoyne Hospital, Montreal

H4A 3J1

McGill University Health Center, Montreal

J1H 5H3

CHUS, Sherbrooke

All Listed Sponsors
collaborator

Canadian Cancer Society (CCS)

OTHER

collaborator

Lantheus Medical Imaging

INDUSTRY

collaborator

British Columbia Cancer Agency

OTHER

collaborator

London Health Sciences Centre

OTHER

collaborator

Princess Margaret Hospital, Canada

OTHER

collaborator

Tom Baker Cancer Centre

OTHER

collaborator

McMaster University

OTHER

collaborator

Institute of Health Economics, Canada

OTHER

collaborator

Queen's University

OTHER

lead

Centre hospitalier de l'Université de Montréal (CHUM)

OTHER